Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | TXNRD1 | Q16881 | 6/20 | 0.50 |
| ▸ | TXNRD3 | Q86VQ6 | 6/20 | 0.50 |
| ▸ | TXNRD2 | Q9NNW7 | 6/20 | 0.50 |
| ▸ | FYN | P06241 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alfadex SCHEMBL2229587 | 1.00 | ALDH1A1 (0.53) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| Betadex SCHEMBL306328 | 0.99 | ALDH1A1 (0.51) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| Betadex SCHEMBL21629653 | 0.92 | ALDH1A1 (0.47) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| Betadex SCHEMBL23198883 | 0.89 | ALDH1A1 (0.56) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| SCHEMBL29414129 | 0.88 | ALDH1A1 (0.48) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| Betadex SCHEMBL23198880 | 0.81 | ALDH1A1 (0.59) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| Alfadex SCHEMBL25413932 | 0.78 | ALDH1A1 (0.80) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| Alfadex SCHEMBL25414284 | 0.78 | ALDH1A1 (0.80) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| Betadex SCHEMBL8746198 | 0.76 | ALDH1A1 (0.83) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| Betadex SCHEMBL6516572 | 0.75 | ALDH1A1 (0.80) | ALDH1A1TSHRLMNATDP1TXNRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1421 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260069537-A1 | Stable Aqueous Bendamustine Cyclodextrin Composition | SOFTKEMO PHARMA CORP (CA) | 2026-03-12 | — | — | US | claimed |
| US-12558349-B2 | Methods of treating infections in overweight and obese patients using antibiotics | MELINTA SUBSIDIARY CORP. (US) | 2026-02-24 | — | — | US | claimed |
| EP-4678649-A1 | USE OF SUBSTITUTED CYCLODEXTRIN FOR VIRAL INACTIVATION IN BIOMANUFACTURING | ROQUETTE FRERES (FR) | 2026-01-14 | — | — | EP | claimed |
| WO-2025199580-A1 | MICROPROJECTION ARRAYS | VAXXAS PTY LIMITED (AU) | 2025-10-02 | — | — | WO | claimed |
| EP-2916846-B1 | NEUROACTIVE STEROIDS AND THEIR USE TO FACILITATE NEUROPROTECTION | DRAWBRIDGE PHARMACEUTICALS PTY LTD (AU) | 2025-09-17 | — | — | EP | claimed |
| US-20250186342-A1 | ANTIEMETIC COMBINATIONS | SPES PHARMACEUTICALS INC. | 2025-06-12 | — | — | US | claimed |
| EP-4539934-A1 | TREATMENT FOR GLOMERULAR DISEASES | Zydus Lifesciences Limited (IN) | 2025-04-23 | — | — | EP | claimed |
| CN-119816306-A | Treatment of Aplastic Anemia (AA) | 载度思生命科学有限公司 | 2025-04-11 | — | — | CN | claimed |
| CN-119486735-A | For the treatment of glomerular diseases | 载度思生命科学有限公司 | 2025-02-18 | — | — | CN | claimed |
| CN-119432976-A | Freeze-drying reagent for citric acid determination, biochemical analysis chip and determination method thereof | 北京中生金域诊断技术股份有限公司 | 2025-02-14 | — | — | CN | claimed |
| US-20070191442-A1 | Aqueous Pharmaceutical Formulations of ER-beta Selective Ligands | WYETH (US) | 2007-08-16 | — | — | US | claimed |
| US-7186686-B2 | Containing mixtures of oppositely-charged polypeptides such as insulin-like growth factor and insulin; treatment of type II diabetes | GENENTECH, INC. (US) | 2007-03-06 | — | — | US | claimed |
| WO-2006063154-A1 | COMPOSITION FOR PROTEASOME INHIBITION | PROTEOLIX, INC. (US) | 2006-06-15 | — | — | WO | claimed |
| US-20060128611-A1 | Composition for enzyme inhibition | PROTEOLIX, INC. (US) | 2006-06-15 | — | — | US | claimed |
| US-20030195142-A1 | Formulated composition | OESWEIN JAMES Q (US) | 2003-10-16 | — | — | US | claimed |
| EP-1165119-B1 | COMPOSITION BASED ON OPPOSITELY-CHARGED POLYPEPTIDES | GENENTECH INC (US) | 2003-10-08 | — | — | EP | claimed |
| US-6559122-B1 | Oppositely-charged polypeptides such as insulin-like growth factor (IGF-I) and insulin and an excipient selected from the group consisting of arginine, lysine, glutamate, sodium dodecyl sulfate, etc. | GENENTECH, INC. | 2003-05-06 | — | — | US | claimed |
| WO-2000061177-A9 | COMPOSITION BASED ON OPPOSITELY-CHARGED POLYPEPTIDES | GENENTECH INC (US) | 2002-04-18 | — | — | WO | claimed |
| EP-1165119-A1 | COMPOSITION BASED ON OPPOSITELY-CHARGED POLYPEPTIDES | Genentech, Inc. (US) | 2002-01-02 | — | — | EP | claimed |
| WO-2000061177-A1 | COMPOSITION BASED ON OPPOSITELY-CHARGED POLYPEPTIDES | GENENTECH, INC. (US) | 2000-10-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250186342-A1 | ANTIEMETIC COMBINATIONS | CRH, AVPR2, AVPR1B | ALDH1A1 3109/4885TSHR 1563/4885LMNA 2688/4885 |
| US-20070191442-A1 | Aqueous Pharmaceutical Formulations of ER-beta Selective Ligands | ESR2, ESR1, GPER1 | ALDH1A1 3258/4885TSHR 890/4885LMNA 2655/4885 |
| US-20260069537-A1 | Stable Aqueous Bendamustine Cyclodextrin Composition | TBCD, CTNND1, KIT | ALDH1A1 2231/4885TSHR 3418/4885LMNA 2015/4885 |
| US-12558349-B2 | Methods of treating infections in overweight and obese patients using antibiotics | CUTA, PADI4, FABP4 | ALDH1A1 2750/4885TSHR 1009/4885LMNA 2265/4885 |
| US-20060128611-A1 | Composition for enzyme inhibition | PSMB1, PSMG3, PSMB2 | ALDH1A1 3721/4885TSHR 4745/4885LMNA 2509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.